Total Payments
$4,486
2024 Payments
$1,572
Companies
15
Transactions
160
Medicare Patients
256
Medicare Billing
$29,927
Payment Breakdown by Category
Food & Beverage$4,440 (99.0%)
Education$46.91 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,440 | 159 | 99.0% |
| Education | $46.91 | 1 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,103 | 52 | $0 (2024) |
| Alkermes, Inc. | $746.25 | 31 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $710.26 | 15 | $0 (2024) |
| ITI, Inc. | $454.83 | 15 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $347.04 | 13 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $197.34 | 6 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $187.42 | 4 | $0 (2024) |
| Axsome Therapeutics, Inc. | $156.84 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $139.50 | 3 | $0 (2024) |
| Corium, LLC | $137.97 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,572 | 57 | Neurocrine Biosciences, Inc. ($378.00) |
| 2023 | $1,969 | 70 | ABBVIE INC. ($480.42) |
| 2022 | $887.02 | 29 | ABBVIE INC. ($272.85) |
| 2021 | $58.67 | 4 | AbbVie Inc. ($40.28) |
All Payment Transactions
160 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $96.64 | General |
| 12/13/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $9.53 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/13/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $4.97 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: PSYCHIATRY | ||||||
| 12/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: NEUROSCIENCE | ||||||
| 11/22/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: PSYCHIATRY | ||||||
| 11/14/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $108.85 | General |
| Category: Neuropsychiatry | ||||||
| 11/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: PSYCHIATRY | ||||||
| 11/12/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $10.50 | General |
| Category: CNS | ||||||
| 11/01/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: NEUROSCIENCE | ||||||
| 10/31/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.93 | General |
| Category: Neuropsychiatry | ||||||
| 10/25/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Central Nervous System | ||||||
| 10/22/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: PSYCHIATRY | ||||||
| 10/17/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $27.85 | General |
| Category: CNS | ||||||
| 10/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: NEUROSCIENCE | ||||||
| 10/01/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $6.42 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 09/26/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| 09/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.01 | General |
| Category: NEUROSCIENCE | ||||||
| 09/20/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $8.30 | General |
| Category: CNS | ||||||
| 09/14/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: PSYCHIATRY | ||||||
| 09/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.93 | General |
| Category: Neuropsychiatry | ||||||
| 09/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: NEUROSCIENCE | ||||||
| 08/24/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: PSYCHIATRY | ||||||
| 08/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: NEUROSCIENCE | ||||||
| 08/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 52 | 225 | $33,625 | $15,453 |
| 2021 | 2 | 72 | 122 | $16,375 | $7,300 |
| 2020 | 3 | 132 | 204 | $28,970 | $7,174 |
Total Patients
256
Total Services
551
Medicare Billing
$29,927
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90834 | Psychotherapy, 45 minutes | Office | 2022 | 21 | 163 | $24,450 | $10,886 | 44.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 48 | $5,075 | $2,756 | 54.3% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 14 | 14 | $4,100 | $1,811 | 44.2% |
| 90834 | Psychotherapy, 45 minutes | Office | 2021 | 56 | 76 | $11,400 | $4,650 | 40.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 46 | $4,975 | $2,650 | 53.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 67 | 112 | $14,580 | $3,232 | 22.2% |
| 90834 | Psychotherapy, 45 minutes | Office | 2020 | 40 | 57 | $8,380 | $2,310 | 27.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 25 | 35 | $6,010 | $1,632 | 27.2% |
About Daisy Lara, CRNP
Daisy Lara, CRNP is a Nurse Practitioner healthcare provider based in Kennett Square, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/28/2015. The National Provider Identifier (NPI) number assigned to this provider is 1083081772.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Daisy Lara, CRNP has received a total of $4,486 in payments from pharmaceutical and medical device companies, with $1,572 received in 2024. These payments were reported across 160 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($4,440).
As a Medicare-enrolled provider, Lara has provided services to 256 Medicare beneficiaries, totaling 551 services with total Medicare billing of $29,927. Data is available for 3 years (2020–2022), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Nurse Practitioner
- Other Specialties Psychiatric/Mental Health
- Location Kennett Square, PA
- Active Since 08/28/2015
- Last Updated 06/18/2021
- Taxonomy Code 363L00000X
- Entity Type Individual
- NPI Number 1083081772
Products in Payments
- VRAYLAR (Drug) $1,103
- INGREZZA (Drug) $710.26
- CAPLYTA (Drug) $540.74
- ARISTADA (Drug) $363.65
- LYBALVI (Drug) $338.59
- REXULTI (Drug) $271.96
- SPRAVATO (Drug) $184.33
- Auvelity (Drug) $156.84
- AUSTEDO (Drug) $119.70
- Azstarys (Drug) $97.48
- ABILIFY MAINTENA (Drug) $76.35
- HETLIOZ (Drug) $76.26
- Austedo XR (Drug) $67.72
- AZSTARYS (Drug) $40.49
- Vivitrol (Drug) $24.09
- ABILIFY ASIMTUFII (Drug) $24.02
- Adzenys XR-ODT (Drug) $21.41
- VIVITROL (Drug) $19.92
- COBENFY (Drug) $14.50
- INVEGA SUSTENNA (Drug) $13.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.